We compared the efficacy and safety of three doses of recombinant GLP-1 , ranging from 1.25 to 5.0 pmol/kg/min ( pkm ) and placebo , given by continuous subcutaneous infusion over 3months in combination with metformin and sulphonylurea ( SU ) , to lower haemoglobin A1c ( HbA1c ) , fasting plasma glucose and weight in 95 type 2 diabetes patients with inadequate glycaemic control .